Solid Tumor CAR-T Therapy Approved in China, a World First
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Boundless Bio's reverse merger; CARsgen wins first solid tumor approval for CAR-T
Plus news about Definium Therapeutics, uniQure, MoonLake Immunotherapeutics, Versant Ventures, Corxel Pharmaceuticals and US WorldMeds. 🇨🇳 BOLD gives up: Boundless Bio {$BOLD}, which faced clinical setbacks over the years ...
Solid Tumor CAR-T Therapy Approved in China, a World First
In a landmark advance for cellular immunotherapy, CARsgen Therapeutics has received regulatory approval in China for satricabtagene autoleucel (satri-cel; CT041), the first CAR-T cell therapy globally approved for the treatment of a solid tumor. The National Medical Products Administration (NMPA) of China approved satri-cel for Claudin18.2 (CLDN18.2)-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA) pa…
China has just made a new big leap forward in the development of advanced therapies by becoming the first country in the world to approve CAR-T therapy for a solid tumor. The treatment, developed by CARsgen Therapeutics for gastric cancer, is a milestone in an area where cell therapies have so far shown their greatest success in hematological tumors. Spain also seeks to make its way in this field. One of the areas that still does not have approv…
CARsgen Announces Approval of Satri-cel, the World’s First CAR T-Cell Therapy Product for Solid Tumors
CARsgen Therapeutics announced that the New Drug Application of satricabtagene autoleucel, the autologous humanized Claudin18.2 CAR T-cell therapy product, was approved for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma who have failed at least two prior lines of therapy. [CARsgen Therapeutics] Press Release
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
